Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Surmodics Inc (NQ: SRDX )

41.95 -0.10 (-0.24%)
Streaming Delayed Price Updated: 11:54 AM EDT, Jun 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Surmodics Inc

< Previous 1 2 3 Next >
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Marathon Oil Corporation (NYSE – MRO), Atrion Corporation (Nasdaq – ATRI), Surmodics, Inc. (Nasdaq – SRDX), Akili, Inc. (Nasdaq – AKLI)
From Brodsky & Smith LLC
Via GlobeNewswire
SRDX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Surmodics, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Surmodics Enters into Definitive Agreement to be Acquired by GTCR for $43.00 Per Share in Cash, Representing an Approximate Equity Value of $627 Million
From Surmodics, Inc.
Via Business Wire
Surmodics Reports Second Quarter of Fiscal Year 2024 Financial Results; Updates Fiscal Year 2024 Financial Guidance
From Surmodics, Inc.
Via Business Wire
Surmodics to Report Second Quarter of Fiscal 2024 Financial Results on May 1
From Surmodics, Inc.
Via Business Wire
Surmodics to Participate in Upcoming Investor Conferences in March and April
From Surmodics, Inc.
Via Business Wire
Surmodics Reports First Quarter of Fiscal Year 2024 Financial Results; Updates Fiscal Year 2024 Financial Guidance
From Surmodics, Inc.
Via Business Wire
Surmodics Announces Successful Early Clinical Use of Pounce™ LP (Low Profile) Thrombectomy System, Designed to Address a Critical, Unmet Need by Facilitating Removal of Thrombi and Emboli Below the Knee
From Surmodics, Inc.
Via Business Wire
Surmodics to Report First Quarter of Fiscal 2024 Financial Results on February 1
From Surmodics, Inc. Surmodics, Inc.
Via Business Wire
Surmodics to Host Virtual Annual Meeting of Shareholders
From Surmodics, Inc.
Via Business Wire
Surmodics Announces TRANSCEND Trial 36-Month Data Presented at 50th Annual VEITH Symposium
From Surmodics, Inc.
Via Business Wire
Surmodics Announces 24-Month Data from the SWING Trial Presented at VEITHsymposium
From Surmodics, Inc.
Via Business Wire
Surmodics to Participate in the Piper Sandler Healthcare Conference on November 28
From Surmodics, Inc.
Via Business Wire
Surmodics Reports Fourth Quarter and Fiscal Year 2023 Financial Results; Introduces Fiscal Year 2024 Financial Guidance
From Surmodics, Inc.
Via Business Wire
Surmodics Announces SWING Trial 24-Month Data to be Presented at VEITH Symposium on November 15
From Surmodics, Inc.
Via Business Wire
Surmodics Announces TRANSCEND Trial 36-Month Data to be Presented at 50th Annual VEITH Symposium
From Surmodics, Inc.
Via Business Wire
Surmodics Announces Launch of Preside™ Medical Device Coating Technology, Providing Industry-Leading Lubricity and Durability to a Broader Range of Complex Device Applications
From Surmodics, Inc.
Via Business Wire
Surmodics to Report Fourth Quarter and Fiscal 2023 Financial Results on November 8
From Surmodics, Inc.
Via Business Wire
Surmodics to Participate in Upcoming Investor Conferences in August
From Surmodics, Inc.
Via Business Wire
Surmodics Reports Third Quarter of Fiscal Year 2023 Financial Results; Updates Fiscal Year 2023 Financial Guidance
From Surmodics, Inc.
Via Business Wire
Surmodics to Report Third Quarter of Fiscal 2023 Financial Results on August 2
From Surmodics, Inc.
Via Business Wire
Surmodics Receives FDA Approval for the SurVeil™ Drug-Coated Balloon
From Surmodics, Inc.
Via Business Wire
Surmodics Receives FDA 510(k) Clearance for Pounce™ LP Thrombectomy System
From Surmodics, Inc.
Via Business Wire
Surmodics to Participate in the Jefferies Healthcare Conference on June 8
From Surmodics, Inc.
Via Business Wire
Surmodics Reports Second Quarter of Fiscal Year 2023 Financial Results; Updates Fiscal Year 2023 Financial Guidance
From Surmodics, Inc.
Via Business Wire
Surmodics Announces First Patient Enrolled in PROWL Registry Study Using the Pounce™ Thrombectomy System
From Surmodics, Inc.
Via Business Wire
Surmodics to Report Second Quarter of Fiscal 2023 Financial Results on April 26
From Surmodics, Inc.
Via Business Wire
Surmodics Announces Successful First Patient Use of Sublime™ Radial Access Microcatheter Designed for the Periphery
From Surmodics, Inc.
Via Business Wire
Surmodics to Participate in the 22nd Annual Needham Virtual Healthcare Conference on April 20
From Surmodics, Inc.
Via Business Wire
Surmodics, Inc. (NASDAQ:SRDX) Shareholder Alert: Investigation Concerning Possible Wrongdoing
San Diego, CA -- (SBWIRE) -- 04/05/2023 -- An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Surmodics, Inc. 
Via SBWire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.